Oncology care is increasingly a multidisciplinary endeavour, and radiation therapy
continues to have a key role across the disease spectrum in nearly every cancer. However …

Medulloblastoma (MB) comprises a biologically heterogeneous group of embryonal tumours
of the cerebellum. Four subgroups of MB have been described (WNT, sonic hedgehog …

Medulloblastoma is the most common pediatric malignant brain tumor. Advances in
molecular profiling have uncovered significant heterogeneity among medulloblastomas and …

Radiation-induced second malignancies (RISM) is one of the important late side effects of
radiation therapy and has an impact on optimal treatment decision-making. Many factors …

Radiotherapy with high-energy charged particles has become an attractive therapeutic
option for patients with several tumour types because this approach better spares healthy …

PURPOSE Proton radiotherapy (PRT) may lessen the neuropsychological risk traditionally
associated with cranial radiotherapy for the treatment of pediatric brain tumors by reducing …

Recent research has demonstrated that survivors of childhood cancer are at risk for a myriad
of late effects that affect physical and mental quality of life. We discuss the patterns and …

Immunotherapy is radically changing the clinical management of patients affected by an
increasingly wide array of tumours. However, not all patients achieve long-term clinical …

Cancer therapy with accelerated charged particles is one of the most valuable biomedical
applications of nuclear physics. The technology has vastly evolved in the past 50 years, the …

The recently-defined four molecular subgroups of medulloblastoma have required updating
of our understanding of in vitro models to include molecular classification and risk …